Skip to content
2000
Volume 17, Issue 8
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Nanotechnology has brought about the advent of personalized medicine in the era of targeted therapeutic strategies for cancer therapy. The ability to exploit tumor features for therapeutic gain has made it possible to manufacture more effective nanomedicines for cancer treatment. However, known obstacles, including the inability to overcome pathophysiological barriers of tumors, have impeded disease management. In spite of this, recent efforts have been made to develop more functionalized nanosystems that utilize the active-targeting approach. This article reviews the FDA-approved cancer drug delivery systems in the general framework of personalized nanomedicine. We discuss the latest efforts in the development of functionalized nano-systems, and summarize relevant ongoing preclinical and clinical trials.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520617666170102150730
2017-07-01
2025-12-12
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520617666170102150730
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test